Development
Novartis AG
NVS
$117.69
$0.850.73%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 478.44% | 11.95% | 36.72% | 3.20% | -91.01% |
| Total Depreciation and Amortization | -10.19% | 4.11% | 6.68% | 10.76% | -12.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -560.68% | -55.21% | -105.38% | 458.70% | 108.54% |
| Change in Net Operating Assets | -654.14% | 263.39% | -43.33% | -1.89% | -77.34% |
| Cash from Operations | -22.28% | 0.19% | -4.77% | 79.32% | 5.84% |
| Capital Expenditure | -32.68% | -18.10% | -18.18% | 7.78% | 33.48% |
| Sale of Property, Plant, and Equipment | 60.78% | 155.00% | -433.33% | -3.03% | 37.84% |
| Cash Acquisitions | -200.00% | -- | -1,100.00% | 96.84% | 99.44% |
| Divestitures | 60.00% | -75.00% | 223.08% | -750.00% | -133.33% |
| Other Investing Activities | -20.22% | -73.27% | 92.87% | 4.37% | -123.73% |
| Cash from Investing | -19.97% | -142.55% | 90.94% | 13.41% | -132.15% |
| Total Debt Issued | 145.65% | -- | -- | 112.89% | -7,575.00% |
| Total Debt Repaid | 200.00% | -31.07% | 136.97% | 2.60% | 97.95% |
| Issuance of Common Stock | -- | -- | -116.67% | 69.15% | -- |
| Repurchase of Common Stock | 53.10% | 40.21% | -8.95% | -13.53% | -1,709.46% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 3.34% | -- |
| Other Financing Activities | 169.64% | 8,032.56% | 54.17% | -868.18% | -900.00% |
| Cash from Financing | 84.80% | 82.44% | -57.99% | 3.42% | -22.85% |
| Foreign Exchange rate Adjustments | 13.48% | -107.50% | 98.08% | 360.98% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 181.72% | -70.20% | 89.10% | 210.24% | -123.27% |